Delivery Order SPE2DR25D2005-SPE2DR26FE7R5
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,771.30 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 ml pens on December 18, 2025, with a completion deadline of December 19, 2025. This firm fixed-price, non-set-aside delivery order is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,767.23 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens on November 13, 2025, with an ultimate completion date of November 14, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive procurement process. The product will be delivered to the company's location in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication, consistent with...
- The Defense Logistics Agency awarded a delivery order valued at $4,709.83 to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pens on November 17, 2025, with completion scheduled for November 18, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a prescription diabetes medication, consistent with AmerisourceBergen's extensive...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,081.35 to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 mL pens on September 12, 2025, with completion expected by September 15, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control in patients with type 2...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,344.41 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pens on September 10, 2025, with completion expected by September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a branded pharmaceutical product used in diabetes management,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,927.16 to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens (0.5 mL) on October 28, 2025, with an ultimate completion date of October 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a pharmaceutical product used for diabetes...
- The Defense Logistics Agency (DLA) awarded a $12,961.12 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pens on December 10, 2025, with completion scheduled for December 11, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Mounjaro is a prescription medication used for diabetes management, representing one of many pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,536.80 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 mL pens on December 16, 2025. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of December 17, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, reflecting the critical pharmaceutical supply needs of the...
- The Defense Logistics Agency awarded a delivery order valued at $16,763.66 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 ml pens on November 10, 2025, with a completion date of November 12, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a prescription medication used in diabetes management, aligning with...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $11,698.99 for Mounjaro 10 mg/0.5 ml pens on November 24, 2025, with completion scheduled for November 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication, consistent with AmerisourceBergen's extensive portfolio of pharmaceutical products...
- SPE2DR25D2005Indefinite Delivery Contract
- SPE2DR25D2005-SPE2DR26FE7R5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,841.40 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 ml pens on November 26, 2025. This competitively awarded, non-set-aside delivery order carries a firm fixed price and is scheduled for completion by November 28, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control in patients with type 2 diabetes. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999 million and extends through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems and other federal agencies worldwide. The company's significant presence in the DLA Medical Supply Chain reflects its capability to fulfill open competition federal procurement requirements across multiple therapeutic domains, including specialty medications, vaccines, and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 11/25/25 |